Genomic testing is becoming mainstream for patients. Companies like 23andMe are bringing affordable testing options to the market and allowing patients to learn more about their genetic makeups. This leads to better care and treatments.

 

If you ask researchers about this trend, they’ll most likely say that the real value of more people participating in genomic testing is that it provides an opportunity to test their theories through analysis of de-identified genomic data of certain patient sets.

 

In the above video, Steve Schwartz, vice president of business development and strategy at 23andMe, talks about the company’s approach to bringing genetic testing to the masses, and how data can be useful in research that ultimately can improve patient care.

 

Watch the clip and let me know what questions you have. What value do you see in the availability of more genomic data?